High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 101–200 of 960
A review of current and novel therapies for idiopathic pulmonary fibrosis.
Rafii, R., Juarez, M. M., Albertson, T. E., & Chan, A. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2012.12.07 · Cited by 175
Cao, H., Wang, C., Chen, X., Hou, J., Xiang, Z., Shen, Y., & Han, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-28968-9 · Cited by 141
Salisbury, M. L., Lynch, D. A., van Beek, E. J. R., Kazerooni, E. A., Guo, J., Xia, M., Murray, S., Anstrom, K. J., Yow, E., Martinez, F. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1385oc · Cited by 136
Exhaled markers of oxidative stress in idiopathic pulmonary fibrosis
Psathakis, K., Mermigkis, D., Papatheodorou, G., Loukides, S., Panagou, P., Polychronopoulos, V., Siafakas, N. M., & Bouros, D. (2006) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2006.01636.x · Cited by 136
Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Estornut, C., Milara, J., Bayarri, M. A., Belhadj, N., & Cortijo, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794997 · Cited by 161
“This study showed the three-drug therapy preserved VC and DLCO in IPF patients better than standard therapy (Demedts et al., 2005) (ClinicalTrials.”
ResultBai, X., Chen, Q., Li, F., Teng, Y., Tang, M., Huang, J., Xu, X., & Zhang, X. (2024) · Nature Communications · doi:10.1038/s41467-024-51056-8 · Cited by 151
Interstitial lung disease in systemic sclerosis
Bussone, G., & Mouthon, L. (2010) · Autoimmunity Reviews · doi:10.1016/j.autrev.2010.09.012 · Cited by 150
TGF-β : Titan of Lung Fibrogenesis
Yue, X., Shan, B., & A. Lasky, J. (2010) · Current Enzyme Inhibition · doi:10.2174/157340810791233033 · Cited by 130
Idiopathic Pulmonary Fibrosis: Evolving Concepts
Ryu, J. H., Moua, T., Daniels, C. E., Hartman, T. E., Yi, E. S., Utz, J. P., & LIMPER, A. H. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.03.016 · Cited by 143
Lin, H., & Jiang, S. (2015) · PubMed · doi:10.3978/j.issn.2072-1439.2015.04.17 · Cited by 133
“Triple combination therapy with N-acetylcysteine, prednisolone and azathioprine, was ever commenced in many patients with IPF based on the IFIGENIA study (64).”
Biopsy-proved Idiopathic Pulmonary Fibrosis: Spectrum of Nondiagnostic Thin-Section CT Diagnoses
Sverzellati, N., Wells, A. U., Tomassetti, S., Desai, S. R., Copley, S. J., Aziz, Z. A., Zompatori, M., Chilosi, M., Nicholson, A. G., Poletti, V. E., et al. (2010) · Radiology · doi:10.1148/radiol.0990898 · Cited by 141
Self-citationHOMMA, S., AZUMA, A., TANIGUCHI, H., OGURA, T., MOCHIDUKI, Y., SUGIYAMA, Y., NAKATA, K., YOSHIMURA, K., TAKEUCHI, M., KUDOH, S., et al. (2012) · Respirology · doi:10.1111/j.1440-1843.2012.02132.x · Cited by 127
Dysregulation of metabolic pathways in pulmonary fibrosis
Rajesh, R., Atallah, R., & Bärnthaler, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108436 · Cited by 139
Gong, Y., Wang, N., Liu, N., & Dong, H. (2019) · DNA and Cell Biology · doi:10.1089/dna.2018.4541 · Cited by 131
“Erastin inhibits cysteine transporter activity and induces the decrease of GSH and GPX4 activity, resulting in iron-or 15-LOX-dependent lipid peroxidation-induced cell death (Friedmann Angeli et al. , 2014; Yang et al. , 2016).”
InfluentialNormativa sobre el diagnóstico y tratamiento de la fibrosis pulmonar idiopática
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2013.03.011 · Cited by 142
Idiopathic pulmonary fibrosis: An update
Spagnolo, P., Sverzellati, N., Rossi, G., Cavazza, A., Tzouvelekis, A., Crestani, B., & Vancheri, C. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.982165 · Cited by 120
Lombardi, R., Rodríguez, G., Chen, S. N., Ripplinger, C. M., Li, W., Chen, J., Willerson, J. T., Betocchi, S., Wickline, S. A., Efimov, I. R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.790501 · Cited by 130
IPF: new insight on pathogenesis and treatment
Harari, S., & Caminati, A. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02305.x · Cited by 118
Reducing protein oxidation reverses lung fibrosis
Anathy, V., Lahue, K. G., Chapman, D. G., Chia, S. B., Casey, D. T., Aboushousha, R., van der Velden, J. L. J., Elko, E., Hoffman, S. M., McMillan, D. H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0090-y · Cited by 120
Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis
Korthagen, N. M., van Moorsel, C. H. M., Barlo, N. P., Ruven, H. J. T., Kruit, A., Heron, M., van den Bosch, J. M. M., & Grutters, J. C. (2011) · Respiratory Medicine · doi:10.1016/j.rmed.2010.09.012 · Cited by 119
“Although clinical trials show that some improvement in lung function deterioration canbe achieved, there is currently no therapy available that has a proven long-termeffect on survival.(5,6) Lung transplantation remains the only option for those who qualify, but mortality on the waiting list is high.”
BackgroundMyllärniemi, M., & Kaarteenaho, R. (2015) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v2.26385 · Cited by 117
“Initial clinical reports on the efficacy of NAC were based on the Ifigenia study, where a three-drug regimen (prednisone, azathioprine, and NAC) was reported to be more efficient than the two-drug therapy (prednisone and azathioprine) that was being used conventionally to treat IPF (60).”
MethodKalchiem‐Dekel, O., Galvin, J. R., BURKE, A. P., Atamas, S. P., & Todd, N. W. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120476 · Cited by 129
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Khor, Y. H., Ng, Y., Barnes, H., Goh, N. S. L., McDonald, C. F., & Holland, A. E. (2020) · European Respiratory Review · doi:10.1183/16000617.0158-2019 · Cited by 127
The role for N-acetylcysteine in the management of COPD
Dekhuijzen, P., & van Beurden, W. (2006) · International Journal of COPD · doi:10.2147/copd.2006.1.2.99 · Cited by 129
“Reproduced with permission of the European Respiratory Society Journals Ltd. International Journal of COPD 2006:1(2) 105 double-blind, randomised, placebo-controlled study that assessed the effectiveness over 1 year of high-dose NAC (1800 mg daily) on top of the recommended standard therapy of prednisone–azathioprine…”
BackgroundAn Inhibitor of NADPH Oxidase-4 Attenuates Established Pulmonary Fibrosis in a Rodent Disease Model
Jarman, E. R., Khambata, V. S., Cope, C., Jones, P., Roger, J., Ye, L. Y., Duggan, N., Head, D., Pearce, A., Press, N. J., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0174oc · Cited by 115
Oral N-acetylcysteine improves cone function in retinitis pigmentosa patients in phase I trial
Campochiaro, P. A., Iftikhar, M., Hafiz, G., Akhlaq, A., Tsai, G., Wehling, D., Lu, L., Wall, G. M., Singh, M. S., & Kong, X. (2019) · Journal of Clinical Investigation · doi:10.1172/jci132990 · Cited by 115
“In general, patients with advanced disease and small central islands of remaining visual field at baseline tended to show little or no change in macular sensitivity during NAC treatment (Supplemental Figures 15, 16, 18, 19, 23, 24, 26, 33, 40, and 41).”
Systemic sclerosis and its pulmonary complications in The Netherlands: an epidemiological study
Vonk, M. C., Broers, B., Heijdra, Y. F., Ton, E., Snijder, R. J. R., van Dijk, A. P. J., van Laar, J. M., Bootsma, H., van Hal, P. T. W., van den Hoogen, F. H. J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091710 · Cited by 131
Newton, R., Leigh, R., & Giembycz, M. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.003 · Cited by 132
“Prednisolone (tapering from 0.5 mg/day to 10–20 mg/day), combined with azathioprine (2 mg/kg, maximum 150 mg/day) and N-acetylcysteine (600 mg three times a day) has been shown to have a significantly better treatment effect than prednisolone and azathioprine alone (Demedts et al., 2005).”
InfluentialVeith, C., Boots, A. W., Idris, M., van Schooten, F., & van der Vliet, A. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7742 · Cited by 121
“In the PANTHER trial, no significant improvement of lung function could be observed in mild-to-moderate IPF compared with the placebo (84), whereas it was reported before in the IFIGENIA trial that the same dose of NAC in combination with prednisone and azathioprine reduced decline of lung function (45).”
ResultRudd, R. M., Prescott, R. J., Chalmers, J. C., Johnston, I. D. A., & for the Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society (2007) · Thorax · doi:10.1136/thx.2005.045591 · Cited by 113
Use of animal models in IPF research
Carrington, R., Jordan, S., Pitchford, S. C., & Page, C. P. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.07.002 · Cited by 116
Salisbury, M. L., Xia, M., Zhou, Y., Murray, S., Tayob, N., Brown, K. K., Wells, A. U., Schmidt, S. L., Martínez, F. J., & Flaherty, K. R. (2015) · CHEST Journal · doi:10.1378/chest.15-0530 · Cited by 124
Predicting Pulmonary Fibrosis Disease Course From Past Trends in Pulmonary Function
Schmidt, S. L., Tayob, N., Han, M. K., Zappala, C. J., Kervitsky, D. J., Murray, S., Wells, A. U., Brown, K. K., Martínez, F. J., & Flaherty, K. R. (2013) · CHEST Journal · doi:10.1378/chest.13-0844 · Cited by 116
Shin, D.-H., Park, H.-M., Jung, K.-A., Choi, H.-G., Kim, J.-A., Kim, D.-D., Kim, S. G., Kang, K. W., Ku, S. K., Kensler, T. W., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.01.021 · Cited by 111
“Patients with IPF have increased markers of oxidative stress and NAC has been the only therapeutic means to preserve lung function in these patients [36].”
BackgroundFBW7 Mediates Senescence and Pulmonary Fibrosis through Telomere Uncapping
Wang, L., Chen, R., Li, G., Wang, Z., Liu, J., Liang, Y., & Liu, J.-P. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.004 · Cited by 109
Servettaz, A., Guilpain, P., Goulvestre, C., Chéreau, C., Hercend, C., Nicco, C., Guillevin, L., Weill, B. J., Mouthon, L., & Batteux, F. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067504 · Cited by 108
Pulmonary Function and Survival in Idiopathic vs Secondary Usual Interstitial Pneumonia
Strand, M. J., Sprunger, D. B., Cosgrove, G. P., Pérez, E. R. F., Frankel, S. K., Huie, T. J., Olson, A. L., Solomon, J. J., Brown, K. K., & Swigris, J. J. (2014) · CHEST Journal · doi:10.1378/chest.13-2388 · Cited by 117
Xie, T., Liang, J., Guo, R., Liu, N., Noble, P. W., & Jiang, D. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00222.2010 · Cited by 107
“Although recent reports have utilized miRNA array analysis to identify critical miRNAs in fibrogenesis in IPF patients (45), as well as bleomycin-treated mouse lungs (36), systematic analysis of miRNA expression in the diseases and in animal models is Address for reprint requests and other correspondence: D. Jiang, Di…”
BackgroundInfluentialsection, I., Žůrková, M., IPF registry, Kriegová, E., Kolek, V., Lošťáková, V., Šterclová, M., Bartoš, V., Doubková, M., Binková, I., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-0977-2 · Cited by 123
“The majority of patients enrolled by December 2014 obtained together with pirfenidone NAC at 3 × 600 mg based on recommendation from the clinical trials [25] and Czech IPF guidelines [24].”
MethodDoherty, E., Oaks, Z., & Perl, A. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5702 · Cited by 106
Depression in patients with idiopathic pulmonary fibrosis
Akhtar, A. A., Ali, M. A., & Smith, R. P. (2013) · Chronic Respiratory Disease · doi:10.1177/1479972313493098 · Cited by 117
The Syndrome of Combined Pulmonary Fibrosis and Emphysema
Cottin, V., & Cordier, J.-F. (2009) · CHEST Journal · doi:10.1378/chest.09-0538 · Cited by 114
Gharaee‐Kermani, M., Gyetko, M. R., Hu, B., & Phan, S. H. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9216-x · Cited by 112
Antioxidants in cystic fibrosis
Cantin, A. M., White, T. B., Cross, C. E., Forman, H. J., Sokol, R. J., & Borowitz, D. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.09.022 · Cited by 143
“azathioprine in patients with idiopathic pulmonary fibrosis, a chronic respiratory disease characterized by lung inflammation, high lung oxidant stress, and low ELF GSH, was associated with a slower deterioration in lung function over a 1-year treatment period [89].”
BackgroundMarigliano, B., Soriano, A., Margiotta, D. P. E., Vadacca, M., & Afeltra, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.001 · Cited by 114
Treatment of idiopathic pulmonary fibrosis: a network meta-analysis
Rochwerg, B., Neupane, B., Zhang, Y., Garcia, C. C., Raghu, G., Richeldi, L., Brozek, J., Beyene, J., & Schünemann, H. (2016) · BMC Medicine · doi:10.1186/s12916-016-0558-x · Cited by 101
“IFIGENIA 2005 [36] Multicenter (36) Europe n = 182 No Histologic or radiologic pattern of UIP with other causes ruled out.”
BackgroundBajwah, S., Ross, J. R., Peacock, J. L., Higginson, I. J., Wells, A. U., Patel, A. S., Koffman, J., & Riley, J. (2012) · Thorax · doi:10.1136/thoraxjnl-2012-202040 · Cited by 108
Song, J. W., Song, J., & Kim, D. S. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.012 · Cited by 112
Li, X., Zhu, L., Wang, B., Yuan, M., & Zhu, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00855 · Cited by 108
Recent Advances in Idiopathic Pulmonary Fibrosis
Noth, I., & Martínez, F. J. (2007) · CHEST Journal · doi:10.1378/chest.06-1927 · Cited by 109
N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition
Felton, V., Borok, Z., & Willis, B. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00009.2009 · Cited by 113
“Most importantly, oral NAC administered to patients with IPF preserved clinical pulmonary function over a period of 1 year (10).”
BackgroundPathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis
Loomis-King, H. A., Flaherty, K. R., & Moore, B. B. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.03.015 · Cited by 113
“treated with azathioprine/prednisone/placebo [27].”
Metabolic control of T cell activation and death in SLE
Fernandez, D., & Perl, A. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.07.041 · Cited by 96
“In a one-year study of IPF patients treated with prednisone and azathioprine, addition of NAC (3×600 mg/d) improved vital capacity and reduced myelotoxicity in comparison to placebo.”
Trivedi, R., Redente, E. F., Thakur, A., Riches, D. W. H., & Kompella, U. B. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/50/505101 · Cited by 97
“A number of other drugs have been evaluated in clinical trials, including interferon-γ [6], warfarin [7], pirfenidone [8], etanercept [9], imatinib [10], bosentan [11, 12], ambrisentan [13], N-acetyl cysteine [14], anti-TGF-β antibody (GC-1008; [13]), TGFβR1 inhibitorSB-525334 [15], αvβ6 antibody [16], P144—a peptide…”
BackgroundLife Extension by Diet Restriction and N-Acetyl-L-Cysteine in Genetically Heterogeneous Mice
Flurkey, K., Astle, C. M., & Harrison, D. E. (2010) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glq155 · Cited by 88
Antioxidant Therapy for Idiopathic Pulmonary Fibrosis
Hunninghake, G. W. (2005) · New England Journal of Medicine · doi:10.1056/nejme058210 · Cited by 98
Epidemiology and Management of Common Pulmonary Diseases in Older Persons
Akgun, K. M., Crothers, K., & Pisani, M. (2012) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glr251 · Cited by 95
“Combination therapy with prednisone, azathioprine, and N-acetylcysteine may slow decline in forced vital capacity compared with prednisone and azathioprine alone, but the clinical significance of these findings is not clear (267,268).”
BackgroundLung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial
the Ifigenia study group*, Behr, J., Demedts, M., Buhl, R., Costabel, U., Dekhuijzen, R. P., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., et al. (2009) · Respiratory Research · doi:10.1186/1465-9921-10-101 · Cited by 94
Self-citationTreatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review
Iqbal, K., & Kelly, C. A. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15612250 · Cited by 107
John, A. E., Luckett, J., Tatler, A. L., Awais, R. O., Desai, A., Habgood, A., Ludbrook, S. B., Blanchard, A. D., Perkins, A. C., Jenkins, G. R., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120592 · Cited by 102
“Although novel drug-based therapies such as N-acetyl cysteine (4) and Pirfenidone (Intermune) (5) have shown encouraging responses in clinical trials, to date, no therapy has successfully modified the disease course.”
BackgroundCotter, M. A., Thomas, J., Cassidy, P., Robinette, K., Jenkins, N., Florell, S. R., Leachman, S., Samlowski, W. E., & Grossman, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1187 · Cited by 92
“It has been safely administered over long periods to large numbers of patients with idiopathic pulmonary fibrosis (15) and short-term to protect against contrast-induced nephropathy (36).”
BackgroundVayalil, P. K., Iles, K. E., Choi, J., Yi, A., Postlethwait, E. M., & Liu, R.-M. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00128.2007 · Cited by 92
“It has been reported that aerosol administration of GSH or NAC restored GSH concentration in lung lining fluid and slowed the deterioration of lung functions in idiopathic pulmonary fibrosis (IPF) and cystic fibrosis patients (2, 4, 9, 14, 16, 40), indicating a potential therapeutic value of GSH/NAC in the treatment o…”
BackgroundWijsenbeek, M. S., & Culver, D. A. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.08.015 · Cited by 97
Serum levels of oxidative stress as a marker of disease severity in idiopathic pulmonary fibrosis
Daniil, Z. D., Papageorgiou, E., Koutsokera, A., Κostikas, Κ., Kiropoulos, T. S., Papaioannou, A. Ι., & Gourgoulianis, K. I. (2006) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2006.10.005 · Cited by 91
LOX/LOXL in pulmonary fibrosis: potential therapeutic targets
Chen, L., Li, S., & Li, W. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1550649 · Cited by 96
“A double-blind, randomised, placebocontrolled multicentre study that assessed the effectiveness of a high oral dose of NAC (600mg, three times daily) added to standard therapy with prednisone plus azathioprine was conducted in patients with IPF, and the results showed that the effects of NAC on the primary end points…”
MethodOxidative stress contributes to the induction and persistence of TGF-β1 induced pulmonary fibrosis
Cui, Y., Robertson, J. V., Maharaj, S. S., Waldhauser, L., Niu, J., Wang, J., Farkas, L., Kolb, M. R. J., & Gauldie, J. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.04.005 · Cited by 93
Targeting NOX enzymes in pulmonary fibrosis
Hecker, L., Cheng, J., & Thannickal, V. J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1012-7 · Cited by 89
Molecular and cellular mechanism of lung injuries due to exposure to sulfur mustard: a review
Ghanei, M., & Harandi, A. A. (2011) · Inhalation Toxicology · doi:10.3109/08958378.2011.576278 · Cited by 94
Nakamura, T., Matsushima, M., Hayashi, Y., Shibasaki, M., Imaizumi, K., Hashimoto, N., Shimokata, K., Hasegawa, Y., & Kawabe, T. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0338oc · Cited by 94
Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis
Johannson, K. A., Vittinghoff, E., Morisset, J., Lee, J. S., Balmes, J. R., & Collard, H. R. (2017) · European Respiratory Journal · doi:10.1183/13993003.02406-2016 · Cited by 101
Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside
Ghonim, M. A., Boyd, D. F., Flerlage, T., & Thomas, P. G. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170499 · Cited by 95
“For a time, after the positive results of the 2004 IFGENIA study (143), which demonstrated improvements in lung function in patients treated with NAC in combination with prednisone and azathioprine, NAC was frequently prescribed by pulmonologists (144).”
ResultSystemic sclerosis - continuing progress in developing clinical measures of response.
Furst, D. E., Khanna, D., Matucci‐Cerinic, M., Clements, P. J., Steen, V. D., Pope, J. E., Merkel, P. A., Foeldvari, I., Seibold, J. R., Pittrow, D., et al. (2007) · PubMed · Cited by 93
Kinnula, V. L., & Myllärniemi, M. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1942 · Cited by 97
“Free radical reactions have been suggested to play a contributory role in the development of interstitial lung disorders including IPF, either directly or through inflammatory stimuli (30, 49, 62, 111).”
S2K-Leitlinie zur Diagnostik und Therapie der idiopathischen Lungenfibrose
Behr, J., Günther, A., Ammenwerth, W., Bittmann, I., Bonnet, R. B., Buhl, R., Eickelberg, O., Ewert, R., Gläser, S., Gottlieb, J., et al. (2013) · Pneumologie · doi:10.1055/s-0032-1326009 · Cited by 110
Self-citationDelivery and Safety of Inhaled Interferon-γ in Idiopathic Pulmonary Fibrosis
Diaz, K. T., Skaria, S., Harris, K., Solomita, M., Lau, S., Bauer, K., Smaldone, G. C., & Condos, R. (2012) · Journal of Aerosol Medicine and Pulmonary Drug Delivery · doi:10.1089/jamp.2011.0919 · Cited by 92
Endpoints for clinical trials of sarcoidosis.
Baughman, R. P., Drent, M., Culver, D. A., Grutters, J. C., Handa, T., Humbert, M. J. C., Judson, M. A., Lower, E. E., Mana, J., Pereira, C. A., et al. (2012) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 85
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
Spagnolo, P., Maher, T. M., & Richeldi, L. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.04.005 · Cited by 94
Outcomes in idiopathic pulmonary fibrosis: A meta-analysis from placebo controlled trials
Atkins, C., Loke, Y. K., & Wilson, A. M. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.11.007 · Cited by 93
“Although few have shown evidence of benefit (nacetylcysteine [9], pirfenidone [10] and BIBF-1120 [11]), a pooled analysis of outcomes in the control arms represents a unique opportunity to evaluate the natural history of IPF in a large cohort of patients undergoing rigorous follow-up.”
BackgroundLin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 91
Adamy, C., Mulder, P. G. H., Khouzami, L., Andrieu‐Abadie, N., Defer, N., Candiani, G., Pavoine, C., Caramelle, P., Souktani, R., Corvoisier, P. L., et al. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.06.010 · Cited by 86
“Of note, the well-being of the patients affected with those diseases is improved by treatment with the glutathione precursor N-acetylcysteine (NAC) [13, 14, 18, 19].”
BackgroundAnathy, V., Roberson, E. C., Guala, A. S., Godburn, K. E., Budd, R. C., & Janssen-Heininger, Y. M. W. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4281 · Cited by 94
“Multimers of death receptor ligands such as TNF and FasL are efficient in triggering oligomerization of death receptors in vitro and in vivo, which is important in effective induction of apoptosis (36, 86).”
BackgroundInfluentialMurthy, S., Adamcakova-Dodd, A., Perry, S. S., Tephly, L. A., Keller, R. M., Metwali, N., Meyerholz, D. K., Wang, Y., Glogauer, M., Thorne, P. S., et al. (2009) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.90590.2008 · Cited by 84
“A recent study revealed that administration of N-acetylcysteine, together with traditional anti-inflammatory agents, improved lung function in patients with idiopathic pulmonary fibrosis (11).”
BackgroundRivera‐Ortega, P., Hayton, C., Blaikley, J., Leonard, C. T., & Chaudhuri, N. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618800618 · Cited by 90
Assessment of Mitochondrial Dysfunction in Lymphocytes of Patients with Systemic Lupus Erythematosus
Perl, A., Hanczko, R., & Doherty, E. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-60761-720-4_4 · Cited by 82
Baughman, R. P., Meyer, K. C., Nathanson, I. T., Angel, L. F., Bhorade, S. M., Chan, K. M., Culver, D. A., Harrod, C. G., Hayney, M. S., Highland, K. B., et al. (2012) · CHEST Journal · doi:10.1378/chest.12-1044 · Cited by 88
Harvey, B. H., Joubert, C., du Preez, J. L., & Berk, M. (2008) · Neurochemical Research · doi:10.1007/s11064-007-9466-y · Cited by 80
Margaritopoulos, G., Vasarmidi, E., & Antoniou, K. (2016) · Core Evidence · doi:10.2147/ce.s76549 · Cited by 81
“Subsequently, a much criticized study, in which the combination of prednisolone, azathioprine, and N-acetyl-cysteine (NAC) was compared with prednisolone and azathioprine, showed a significant reduction in the rate of decline of the forced vital capacity (FVC) and of the diffusing capacity for carbon monoxide (DL CO )…”
Jiang, C., Huang, H. F., Liu, J., Wang, Y., Lu, Z., & Xu, Z. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047024 · Cited by 82
Faverio, P., Giacomi, F. D., Sardella, L., Fiorentino, G., Carone, M., Salerno, F. G., Ora, J., Rogliani, P., Pellegrino, G. M., Papa, G. F. S., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0643-3 · Cited by 90
Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study
Harari, S., Caminati, A., Albera, C., Vancheri, C., Poletti, V., Pesci, A., Luppi, F., Saltini, C., Agostini, C., Bargagli, E., et al. (2015) · Respiratory Medicine · doi:10.1016/j.rmed.2015.04.010 · Cited by 78
Pirfenidone Clinical Study Group in Japan, Taniguchi, H., Kondoh, Y., Ebina, M., Azuma, A., Ogura, T., Taguchi, Y., Suga, M., Takahashi, H., Nakata, K., et al. (2011) · Respiratory Research · doi:10.1186/1465-9921-12-93 · Cited by 78
“Our results are considerably similar to those of extended analysis of the IFIGENIA study investigating the effect of N-acetylcysteine (NAC) in IPF, which also showed significance of a 5% threshold [26].”
BackgroundInfluentialSafety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study
Günther, A., Enke, B., Markart, P., Hammerl, P., Morr, H., Behr, J., Stähler, G., Seeger, W., Grimminger, F., Leconte, I., et al. (2007) · European Respiratory Journal · doi:10.1183/09031936.00149205 · Cited by 78
“In light of the overall limited influence of other treatment modalities in IPF [23-25], further assessment of the therapeutic efficacy of bosentan in IPF seems to be warranted.”
BackgroundSelf-citationStem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal
Τzouvelekis, Α., Koliakos, G., Ntolios, P., Baira, I., Bouros, E., Oikonomou, A., Zissimopoulos, A., Kolios, G. C., Kakagia, D. D., Paspaliaris, V., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-182 · Cited by 87
“Conventional therapeutic approach includes combination of corticosteroids, anti-oxidants, immunosuppressants and immunomodulatory anti-fibrotic agents [11-16].”
BackgroundA nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan
Okamoto, T., Miyazaki, Y., Ogura, T., Chida, K., Kohno, N., Kohno, S., Taniguchi, H., Akagawa, S., Mochizuki, Y., Yamauchi, K., et al. (2013) · Respiratory Investigation · doi:10.1016/j.resinv.2013.03.004 · Cited by 76
“We should also evaluate the effectiveness of pirfenidone and N-acetylcysteine, agents that have demonstrably prevented the decline of pulmonary function in recent studies [27,28].”
BackgroundNew Insights into the Role of Oxidative Stress in Scleroderma Fibrosis
Gabrielli, A., Svegliati, S., Moroncini, G., & Amico, D. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010087 · Cited by 87
Challenges in pulmonary fibrosis {middle dot} 5: The NSIP/UIP debate
du Bois, R., & King, T. E. (2007) · Thorax · doi:10.1136/thx.2004.031039 · Cited by 77
Antifibrotic Therapies in the Liver
Schuppan, D., & Mehal, W. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1550055 · Cited by 75
Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis
Moore, M. W., & Herzog, E. L. (2013) · Current Pathobiology Reports · doi:10.1007/s40139-013-0017-8 · Cited by 89
“Indeed, as demonstrated by the IFIGENIA trial, addition of N-acetyl cysteine (NAC) to what at the time was viewed as conventional anti-fibrotic treatment with prednisone and azathioprine, led to improved outcomes [77] in subjects randomized to the treatment arm.”
MethodSafety of N-Acetylcysteine at High Doses in Chronic Respiratory Diseases: A Review
CALVERLEY, P. M. A., Rogliani, P., & Papi, A. A. (2020) · Drug Safety · doi:10.1007/s40264-020-01026-y · Cited by 95
Giacomelli, C., Piccarducci, R., Marchetti, L., Romei, C., & Martini, C. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114812 · Cited by 84
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.